SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Biohaven Highlights BHV-1420 at ASN Kidney Week 2026

Biohaven's oral presentation spotlights BHV-1420, a TRAP degrader designed to selectively remove autoantibodies that drive membranous nephropathy.

BHVN

Related stories